remix therapeutics | Home - Remix Therapeutics

Keyword	CPC	PCC	Volume	Score	Length of keyword
remix therapeutics	0.31	0.6	3420	45	18
remix	0.83	0.1	5690	85	5
therapeutics	0.5	0.1	2337	52	12

Keyword	CPC	PCC	Volume	Score
remix therapeutics	0.38	0.1	4240	56
remix therapeutics stock	1.34	0.6	9952	99
remix therapeutics myb	1.64	0.7	1459	3
remix therapeutics address	1.71	0.1	9131	87
remix therapeutics pipeline	0.46	0.7	4642	84
remix therapeutics cambridge	0.34	0.9	2180	92
remix therapeutics crunchbase	0.38	0.3	9034	76
remix therapeutics watertown ma	0.08	0.3	4199	17
remix therapeutics jobs	0.43	0.6	1554	39
remix therapeutics news	1.77	0.4	2632	67
remix therapeutics pitchbook	0.11	0.1	5398	71
remix therapeutics phone number	0.89	0.6	3644	50
remix therapeutics inc	0.69	0.3	6278	78

Search Results related to remix therapeutics on Search Engine

Home - Remix Therapeutics
remixtx.com

https://www.remixtx.com/

WEBFeb 1, 2024 · Remix™ launched in 2020 with a vision to transform patient's lives through modulation of RNA processing. Our breakthrough science provides a path to identify small molecules that impact the expression of disease driving mRNAs and proteins.

DA: 69 PA: 94 MOZ Rank: 1

About Us - Remix Therapeutics
remixtx.com

https://www.remixtx.com/about/

WEBOur breakthrough science provides a path to identify small molecules that impact the expression of disease driving mRNAs and proteins. With an in-house technology platform built from scratch, we have rapidly generated multiple drug discovery programs that are advancing towards the clinic.

DA: 4 PA: 88 MOZ Rank: 65

Our Science - Remix Therapeutics
remixtx.com

https://www.remixtx.com/science/

WEBDetermined to deliver novel and impactful treatments, Remix™ sets about advancing our breakthrough discoveries into innovative and relevant medicines. Our first act is tackling previously undrugged oncogenic transcription factors to eradicate certain solid tumors and hematological malignancies.

DA: 57 PA: 90 MOZ Rank: 12

Remix Therapeutics™ Closes $60 Million Financing to Advance …
remixtx.com

https://www.remixtx.com/remix-therapeutics-closes-60-million-financing-to-advance-rem-422-pipeline-of-small-molecule-therapies-designed-to-reprogram-rna-processing-to-treat-disease/

WEBCambridge, Mass. (January 3, 2024) – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the close of a $60 million financing led by The Column Group.

DA: 14 PA: 74 MOZ Rank: 82

Remix Therapeutics™ Enters Collaboration with Roche for the …
remixtx.com

https://www.remixtx.com/remix-therapeutics-enters-collaboration-with-roche-for-the-discovery-and-development-of-small-molecule-therapeutics-modulating-rna-processing/

WEBWatertown, Mass. (January 3, 2024) – Remix Therapeutics (Remix), a clinical stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease, today announced a collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery and …

DA: 68 PA: 3 MOZ Rank: 31

Remix Therapeutics Enters Collaboration with Roche for the …
prnewswire.com

https://www.prnewswire.com/news-releases/remix-therapeutics-enters-collaboration-with-roche-for-the-discovery-and-development-of-small-molecule-therapeutics-modulating-rna-processing-302024970.html

WEBJan 3, 2024 · Remix Therapeutics is a clinical stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. The REMaster ™ technology platform...

DA: 83 PA: 68 MOZ Rank: 94

First small-molecule drug targeting RNA gains momentum
nature.com

https://www.nature.com/articles/s41587-020-00788-1.pdf

WEBRNA-targeting drugs. Remix Therapeutics, the latest such contender to emerge, disclosed an $81 million series A round on 8 December and unveiled plans to develop oral drugs that target and...

DA: 55 PA: 57 MOZ Rank: 96

Remix Therapeutics Launches with $81 Million Financing to …
remixtx.com

https://www.remixtx.com/remix-therapeutics-launches-with-81-million-financing-to-develop-small-molecule-therapies-designed-to-reprogram-rna-processing/

WEBDec 8, 2020 · Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. Our REMaster technology platform allows us to identify patterns in RNA processing and exploit them to modulate gene expression.

DA: 3 PA: 74 MOZ Rank: 34

Remix Therapeutics Enters Collaboration with Janssen to …
remixtx.com

https://www.remixtx.com/remix-therapeutics-enters-collaboration-with-janssen-to-advance-small-molecule-therapeutics-using-remaster-drug-discovery-platform-to-modulate-rna-processing/

WEBCambridge, Mass. (February 17, 2022) – Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, today announced a strategic collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson …

DA: 97 PA: 63 MOZ Rank: 58

Remix Therapeutics Launches with $81 Million Financing to …
prnewswire.com

https://www.prnewswire.com/news-releases/remix-therapeutics-launches-with-81-million-financing-to-develop-small-molecule-therapies-designed-to-reprogram-rna-processing-301187843.html

WEBDec 8, 2020 · Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. Our REMaster technology...

DA: 60 PA: 10 MOZ Rank: 10